Sandbox Reserved 1767: Difference between revisions

<StructureSection load='1stp' size='340' side='right' caption='SHOC2-MRAS-PP1C (SMP) Holophosphatase Complex functions as a key regulator of the receptor tyrosine kinase (RTK) signaling pathway by removing an inhibitory phosphate on the RAF family of proteins to allow for MAPK signaling. {{Font color|cyan|SHOC2}} is shown as cyan blue, {{Font color|lime|MRAS}} as lime, and {{Font color|violet|PP1C}} as violet. [https://www.rcsb.org/structure/7UPI PDB: 7UPI]' scene='95/952694/Overall_image/2'>

<scene name='95/952695/Overall_image/2'>The SHOC2-MRAS-PP1C</scene> (SMP) holophosphatase complex functions as a key regulator of the [https://www.nature.com/scitable/topicpage/rtk-14050230/#:~:text=One%20of%20the%20most%20common,anchored%20to%20the%20plasma%20membrane. receptor tyrosine kinase (RTK)] signaling pathway by removing an inhibitory phosphate on the [https://www.sciencedirect.com/science/article/pii/S0167488907001164. RAF] family of proteins to allow for [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536342/. MAPK signaling].<ref name="Kwon">PMID: 35831509</ref> This interaction of the RTK-RAS pathway and the SMP complex drives cell proliferation.<ref name="Hauseman">PMID:35830882</ref> The SMP complex is made of three subunits, SHOC2, PP1C, and MRAS. Each of these subunits has a different shape that corresponds to its different function. <scene name='95/952695/Shoc2intro/1'>The SHOC2 subunit</scene> uses a crescent shape to enhance substrate interactions and complex stability.<ref name="Liau">PMID: 35768504</ref> <scene name='95/952695/Pp1cintro/3'>The PP1C subunit</scene> contains the the catalytic site of the complex which dephosphorylates the N-terminal phosphoserine (NTpS) of RAF.<ref name="Liau">PMID: 35768504</ref> <scene name='95/952694/Pp1ccorrectintro/1'>The MRAS subunit</scene> binds to GTP which causes assembly of the SMP complex. The <scene name='95/952695/413cellmemprotrusion/4'>C-terminus of MRAS</scene> localizes the complex to the cell membrane.<ref name="Liau">PMID: 35768504</ref> Once the SMP compelx is assembled, MRAS can bind to <scene name='95/952695/Raf/3'>RAF</scene>, allowing the [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5000522/. signaling cascade] to continue. Mutations in one or multiple of these subunits can lead to over-activation of the signaling pathway, which may result in cancer and developmental disorders called [https://kidshealth.org/en/parents/rasopathies.html RASopathies].<ref name="Kwon">PMID: 35831509</ref>  

There are many regulatory mechanisms that serve as a lock on this [https://www.cancer.gov/research/key-initiatives/ras/about#:~:text=RAS%20proteins%20are%20important%20for,inactive%20(GDP%20form)%20states. RAS]-[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536342/. MAPK] pathway, decreasing the likelihood of unintentional pathway activation. <ref name="Hauseman">PMID:35830882</ref> One example is <scene name='95/952695/14-3-3/1'>14-3-3</scene>, a protein dimer that keeps inactive RAF localized to the cytoplasm. An <scene name='95/952695/Raf_ntps/1'>N-terminal phosphorylated serine</scene> (NTpS) keeps RAF bound to this protein dimer, and when the SMP complex is assembled, the catalytic subunit, PP1C, removes the phosphate group from Ser259, releasing RAF from <scene name='95/952695/14-3-3/1'>14-3-3</scene>, and activating the RAS-MAPK cell proliferation pathway. <ref name="Hauseman">PMID:35830882</ref>

In all images and animations, {{Font color|cyan|SHOC2}} will be shown as cyan blue, {{Font color|lime|MRAS}} as lime, and {{Font color|violet|PP1C}} as violet. Other important components involved in the function of the SMP complex include the {{Font color|salmon|14-3-3}} dimer and {{Font color|slateblue|Raf}}, which will be shown in salmon and slate-blue, respectively.   

<scene name='95/952695/Shoc2intro/1'>SHOC2</scene> is essential for complex formation. It is a crescent shaped complex that serves as a bridge for PP1C and MRAS, maximizing interaction between the three subunits of the SMP complex <ref name="Hauseman">PMID:35830882</ref>. SHOC2 contains a large leucine rich region (LRR) that provides stability and localizes subunit PP1C to the membrane<ref name="Liau">PMID: 35768504</ref>. SHOC2 only undergoes a <scene name='95/952695/Shoc2_gtp_bound_vs_gdp_bound/1'>6° conformational change</scene> when PP1C and MRAS bind showing it is a [https://www.prosci-inc.com/applications-techniques/5-a-of-antibody-development/scaffold-proteins/. scaffolding] protein that provides a favorable interface for complex formation<ref name="Liau">PMID: 35768504</ref>. SHOC2 depletion is being studied as a therapeutic approach for RAS-driven cancers due to large scale interactions of the subunits being made possible by SHOC2 <ref name="Kwon">PMID: 35831509</ref>. As shown in '''Figure 1 '''SHOC2 and PP1C first engage in binding with each other via an N-terminal <scene name='95/952695/Rvxf_motif/2'>RVXF Motif</scene> on SHOC2 that is complimentary to a binding sequence on PP1C. SHOC2 residues <scene name='95/952695/Shoc2_highlighted_residues/1'>V64 and F66</scene> embed in the complimentary region of PP1C, enhancing SHOC2 affinity for PP1C. SHOC2 binds MRAS-GTP through β strands of a LRR that interacts with a [https://pubmed.ncbi.nlm.nih.gov/21954777/. hydrophobic] region of MRAS-GTP further stabilizing the complex<ref name="Kwon">PMID: 35831509</ref>.

<scene name='95/952695/Pp1cintro/3'>The Protein Phosphatase Complex 1 (PP1C)</scene> subunit contains the catalytic site of the SMP complex. PP1C is a [https://pubmed.ncbi.nlm.nih.gov/30036567/. Phosphatase] enzyme responsible for the removal of a phosphate group on the N-terminal phosphoserine (NTpS) of RAF (Ser259)<ref name="Liau">PMID: 35768504</ref>. The exact mechanism of dephosphorylation is currently unknown, but there are three catalytic metal ions: 2 Mn⁺² and 1 Cl⁻¹ present that coordinate [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3458771/. nucleophilic] water molecules in the active site <ref name="Hauseman">PMID:35830882</ref>. This dephosphorylation event allows for pathway activation, as shown in '''Figure 1''' <ref name="Liau">PMID: 35768504</ref>. Although PP1C can dephosphorylate other proteins independently from the SMP complex, it cannot act on RAF unless bound to the complex because it lacks intrinsic substrate selectivity <ref name="Liau">PMID: 35768504</ref>. SHOC2 and MRAS aid in the specificity of the enzymatic activity. PP1C binds to SHOC2 and MRAS-GTP in a specific orientation that doesn’t change the conformation of the {{Font color|red|catalytic site}} and leaves it accessible for substrate binding as shown in '''Figure 2'''.

PP1C binds to SHOC2 through a hydrophobic N-terminal disordered region that is complimentary to the <scene name='95/952695/Rvxf_motif/2'>RVXF Motif on SHOC2</scene> and adjacent to a catalytic metal ions <ref name="Liau">PMID: 35768504</ref>.  In the RAS/RAF signaling cascade, the region of RAF that is C-terminal to the phosphate group binds to this hydrophobic groove, and the remaining residues bind to the hydrophobic region of SHOC2 <ref name="Hauseman">PMID:35830882</ref>. RAF binding to this region of SHOC2 is what allows PP1C to be specific when in the SMP complex in comparison to PP1C on its own <ref name="Hauseman">PMID:35830882</ref>. Similarly to SHOC2, PP1C does not undergo a <scene name='95/952694/Pp1coverlay/4'>significant conformational change</scene> when SHOC2 and MRAS-GTP bind. The lack of conformational change shows that the structure of PP1C is not dependent on the SMP complex, but in order to act as a phosphatase it must be bound to the complex <ref name="Liau">PMID: 35768504</ref>.  

PP1C is involved in many different cellular signaling pathways including [https://www.ncbi.nlm.nih.gov/books/NBK545161/. protein synthesis], [https://www.ncbi.nlm.nih.gov/books/NBK559006/. muscle contraction,] and even [https://pubmed.ncbi.nlm.nih.gov/11237211. carbohydrate metabolism]<ref name="Kelker">PMID: 18992256</ref>. In all these pathways, including the SMP pathway, PP1C does not exist as a monomer, it is present in [https://byjus.com/neet/what-is-holoenzyme/. holoenzyme] form complex with one of two regulatory subunits ensuring there is no sporadic pathway activation <ref name="Liau">PMID: 35768504</ref>.

[[Image:pic3.jpg|300 px|right|thumb|'''Figure 3:''' MRAS binding sites with SHOC2, PP1C, and RAF (PDB 7DSO) <ref name="Liau">PMID: 35768504</ref>.]]

While <scene name='95/952695/Raf/3'>RAF</scene> is not technically part of the SMP protein complex, it is crucial for advancement in the cell signaling pathway SMP helps mediate. RAF plays many different roles in this pathway and has many different domains. '''Figure 1''' shows RAF has a RAS binding domain (RBD), a <scene name='95/952695/Raf_ntps/3'>N-terminal phosphorylated serine</scene> (NTpS), and a [https://en.wikipedia.org/wiki/Protein_kinase_domain. kinase domain]<ref name="Lavoie">PMID: 35970881</ref>. '''Figure 1''' also shows these domains and mechanistically how RAF is involved in signal advancement or lack thereof. When its N-terminal serine is phosphorylated RAF is bound to a 14-3-3 protein dimer, inactivating the pathway. As shown in '''Figure 1''' the dephosphroylation of Ser259 starts the signaling cascade <ref name="Lavoie">PMID: 35970881</ref>.  

RAS proteins are GTP-dependent [https://pubmed.ncbi.nlm.nih.gov/14604583/. intracellular switches] that are anchored to the plasma membrane. <ref name="Liau">PMID: 35768504</ref> RAS proteins activate RAF kinases through direct binding and membrane recruitment, resulting in RAF dimerization and pathway activation <ref name="Liau">PMID: 35768504</ref>. The SMP complex has specificity for MRAS. Other RAS proteins may bind to SHOC2, but MRAS induces the complex formation with a significantly lower [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004624/. dissociation constant] <ref name="Liau">PMID: 35768504</ref>. There are no known membrane interacting regions on SHOC2 and PP1C, meaning the [https://bio.libretexts.org/Bookshelves/Introductory_and_General_Biology/Book%3A_General_Biology_(Boundless)/03%3A_Biological_Macromolecules/3.05%3A_Lipid_Molecules_-_Phospholipids#:~:text=The%20fatty%20acid%20chains%20are,the%20intracellular%20and%20extracellular%20fluid. hydrophobic fatty acid tail] on MRAS is responsible for recruiting the complex to the cell membrane. This allows only for 2D movement and increasing local concentrations of the players needed in this signaling pathway <ref name="Hauseman">PMID:35830882</ref>.

MRAS contains two regions called Switch I (SWI) and Switch II (SWII) that undergo conformational changes depending if MRAS is bound to GDP or GTP <ref name="Liau">PMID: 35768504</ref>. The conformation of these switches determines if the SMP complex can form or not. Mutations to MRAS can lead to consistent GTP-loading, causing an increase in the formation of the SMP complex as well as consistent activation of the cell-proliferation pathway in the absence of external growth factors.

[[Image:RASRAF.png|410 px|right|thumb|'''Figure 5''': MRAS SWI and SWII open and closed conformations<ref name="Liau">PMID: 35768504</ref>.]]

SHOC2-PP1C-MRAS is a central gatekeeper in receptor tyrosine kinase signaling <ref name="Liau">PMID: 35768504</ref>. '''Figure 1''' shows the specific pathways SHOC2-PP1C-MRAS mediates. When MRAS is bound to GDP, shown in the left of '''Figure 1''', RAF is bound to a 14-3-3 protein dimer restricting it to the cytoplasm. When MRAS-GDP is exchanged for GTP via a nucleotide exchange factor GEF, shown in '''Figure 4''', a conformational change occurs. This change causes a shift from the <scene name='95/952693/Swi_open_conformation/6'>open conformation</scene> to <scene name='95/952693/Switch_i_gtp_bound/11'>closed conformation</scene> of Switch I, shown in '''Figure 5'''. The Switch I (SWI) region is made up of <scene name='95/952694/Mras_switch_i/7'>residues 42-48 of the MRAS domain</scene> <ref name="Kwon">PMID: 35831509</ref>. These residues are crucial for the binding of MRAS, SHOC2, and PP1C because MRAS undergoes a conformational change that allows for SMP complex assembly upon GTP binding <ref name="Hauseman">PMID:35830882</ref>. When GTP is bound to MRAS, it is in the “closed conformation” because hydrogen bond interactions between the γ phosphate of GTP and residues in the SWI region of MRAS cause SWI to adopt a closed conformation <ref name="Hauseman">PMID:35830882</ref>, as seen in '''Figure 5'''. The closed conformation allows for the binding of SHOC2 and PP1C because there is no [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058769/. steric clash] between the <scene name='95/952693/Switch_i_gtp_bound/11'>SWI region of MRAS</scene> and the surface of SHOC2 when GTP is bound <ref name="Kwon">PMID: 35831509</ref>. The only large-scale conformational change occurs in the MRAS subunit <ref name="Liau">PMID: 35768504</ref>. When GDP is bound to the MRAS domain, it is in the “open” conformation. Since the γ-phosphate is not bound to GDP, there are no hydrogen bond interactions with the oxygens of the γ-phosphate group and the MRAS SWI region, causing MRAS to adpot an "open" conformation. Since SHOC2 and PP1C do not undergo much conformational change, they are in a slow equilibrium of binding and unbinding until MRAS binds to GTP allowing MRAS to bind to SHOC2 and PP1C <ref name="Liau">PMID: 35768504</ref>.  

=== Cancer and Rasopathies ===

Common mutations in SHOC2 and PP1C lead to amino acid changes on the interaction surfaces, which can result in [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2692211/. higher binding affinity].<ref name="Lavoie">PMID: 35970881</ref>The interface of SHOC2-PP1C is stabilized by the <scene name='95/952695/Q249k_mutation/1'>Q249K</scene> mutation because this creates a salt bridge with E116 of PP1C. This enhances the binding energy by -22.7 kcal/mol. Mutations to MRAS can result in consistent GTP-loading, increasing the formation of the SMP complex in the absence of external growth factors that are necessary for activation of the pathway in a healthy organism. The majority of wild type MRAS in cells are bound to GDP, whereas the MRAS with the Q71L mutation locked MRAS in the GTP bound state.<ref name="Hauseman">PMID:35830882</ref> In MRAS, <scene name='95/952695/Q249k_mutation/2'>Q71L and G23V</scene> both show increased interaction with other effectors such as BRAF, CRAF, and AF6, consistent with gain-of-function mutations that activate MRAS, leading to GTP-loading.

Mutations in PP1C can trigger increased active site activity, increasing  the RAF proteins that are active and available to bind to RAS. In patients with [https://medlineplus.gov/genetics/condition/noonan-syndrome/#:~:text=Noonan%20syndrome%20is%20a%20condition,many%20other%20signs%20and%20symptoms. Noonan Syndrome], a disease in the RASopathy family, a point mutation of <scene name='95/952695/Q249k_mutation/2'>T68I</scene> MRAS was identified, however the effects this has are unknown.​​<ref name="Young">PMID: 30348783</ref> Universally, when this MAPK cascade is unregulated, cells are able to proliferate regardless of external signals, leading to [https://www.ncbi.nlm.nih.gov/books/NBK20362/. cancer] and/or RASopathies.  

*Sloan August

*Rosa Trippel

*Kayla Wilhoite